Riskpilot← Back to searchSign inGet full accessAvenue Biosciences Oy
OYActiveY-tunnus 3372987-7Viikinkaari 1-aResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20238 employees
Revenue 2025
EUR 40K
EBITDA margin
-3570.5%
-392% vs 2024
Equity ratio
2.3%
Financial strength
Net profit 2025
EUR -1,5M
-504% vs 2024
| Revenue | EUR 40K | — |
| EBITDA | EUR -1,4M | -392% |
| Net profit | EUR -1,5M | -504% |
| Total assets | EUR 594K | -30% |
| Equity | EUR 14K | -98% |
| Employees | 8 | — |
Legal name
Avenue Biosciences Oy
Y-tunnus number
3372987-7
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19. kesäkuuta 2023
Share capital
EUR 0
Employees
8 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Company purpose
Toimialana on bioteknologia sekä alan tutkimus- ja tuotekehitys. Erityisesti yritys tuottaa palveluita terapeuttisten ja muiden bioteknologisten proteiini- tai muiden tuotteiden (mm. monoklonaalisten vasta-aineiden solutuotanto) asiakkaille kansainvälisesti.
Address
Viikinkaari 1-a
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 40 |
| Staff expenses | −138 | −166 | −679 |
| EBITDA | −191 | −290 | −1 428 |
| Depreciation & amort. | −13 | −10 | −48 |
| EBIT | −204 | −300 | −1 476 |
| Net financials | −12 | 49 | −40 |
| Profit before tax | −216 | −251 | −1 516 |
| Tax | −0 | −0 | −0 |
| Net profit | −216 | −251 | −1 516 |
| Item | 2024 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 1 073 | 854 | 594 |
| Equity | 959 | 708 | 14 |
| Long-term debt | 41 | 44 | 408 |
| Short-term debt | 73 | 101 | 173 |
| Total debt | 114 | 145 | 581 |
EBITDA margin
-3570.5%
This company
15.8%
Market median
-22698% vs market
20242025
Equity ratio
2.3%
This company
38.2%
Market median
-94% vs market
20242025
Return on equity
-10876.4%
This company
18.4%
Market median
-59211% vs market
20242025
Net profit margin
-3789.4%
This company
8.1%
Market median
-46883% vs market
20242025
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20242025
Debt / equity
41.66×
This company
0.62×
Market median
-6619% vs market
20242025
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
MC Deputy auditor | Deputy auditor | 2025 |
| Audit | 2025 | |
KM Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2026 | |
| Chairperson | 2026 | |
| Former (1) | ||
| Board of Directors | 2023 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Avenue Biosciences Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marko Christian Saxell | Deputy auditor | 0 companies |
| Valtteri Matti Eemeli Helenius | Audit | 0 companies |
| Katja Marjukka Rosti | Chief Executive Officer | 0 companies |
| Juho Arvo Topias Kellosalo | Board of Directors | 0 companies |
| Ville Oskari Paavilainen | Board of Directors | 0 companies |
| Tero-Pekka Alastalo | Chairperson | 0 companies |